Now, a first-in-human clinical trial is testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal cancers. The results show encouraging signs of safety ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs. The gene-editing innovator is ...

The flexibility of CRISPR/Cas9 editing is severely constrained by the requirement that the modification site is located in close proximity to the landing sequences. Here, authors develop a ...

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology to be approved towards the end of last year, when it was cleared by the FDA for ...

acceptphoto via Shutterstock Who’s up for some CRISPR-y bacon? This week, the Food and Drug Administration approved gene-edited pigs developed by PIC, a biotechnology company specializing in ...

I test preclinici, condotti su topi geneticamente modificati e primati non umani, hanno mostrato una risposta immunitaria solida e duratura, con importanti miglioramenti nei marcatori patologici e ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

La scoperta, pubblicata sulla rivista Science, si deve allo studio durato diversi anni e condotto su topi da ricercatori dell’Università della California a San Diego. Le nuove informazioni ...

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -24.41% and 83.48%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stoc ...

Facendo l’inverso - cellule di topi giovani impiantate su topi anziani - non si è osservata una produzione anomala di tessuto adiposo. Le cellule staminali degli esemplari anziani, quindi ...